Surgery in ovarian cancer
- 1 February 1996
- journal article
- editorial comment
- Published by Wolters Kluwer Health in Current Opinion in Obstetrics and Gynecology
- Vol. 8 (1) , 8-11
- https://doi.org/10.1097/00001703-199602000-00003
Abstract
Critical analysis of the collected evidence on cytoreductive surgery suggests a median survival benefit of 9–12 months in combination with platinum-based chemotherapy. Recently, a randomized study on the value of secondary cytoreduction showed a median survival benefit of 6 months for those with small residual disease after the second operation. Primary cytoreduction is feasible in approximately 70% of patients, with an acceptable level of morbidity The reported evidence justifies a serious attempt at cytoreductive surgery at the first operation by an experienced gynaecological oncologistKeywords
This publication has 0 references indexed in Scilit: